- Home
- FOA vs DBVT Comparison
FOA vs DBVT Comparison
Compare FOA & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- DBVT
- Stock Information
- Founded
- FOA 2013
- DBVT 2002
- Country
- FOA United States
- DBVT France
- Employees
- FOA N/A
- DBVT N/A
- Industry
- FOA Finance Companies
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FOA Finance
- DBVT Health Care
- Exchange
- FOA Nasdaq
- DBVT Nasdaq
- Market Cap
- FOA 248.8M
- DBVT 250.5M
- IPO Year
- FOA N/A
- DBVT N/A
- Fundamental
- Price
- FOA $22.93
- DBVT $10.30
- Analyst Decision
- FOA Buy
- DBVT Buy
- Analyst Count
- FOA 2
- DBVT 4
- Target Price
- FOA $27.50
- DBVT $14.81
- AVG Volume (30 Days)
- FOA 104.1K
- DBVT 25.0K
- Earning Date
- FOA 08-05-2025
- DBVT 07-29-2025
- Dividend Yield
- FOA N/A
- DBVT N/A
- EPS Growth
- FOA N/A
- DBVT N/A
- EPS
- FOA 3.94
- DBVT N/A
- Revenue
- FOA $429,184,000.00
- DBVT $3,497,000.00
- Revenue This Year
- FOA $21.89
- DBVT $1,700.53
- Revenue Next Year
- FOA $8.91
- DBVT $535.67
- P/E Ratio
- FOA $5.86
- DBVT N/A
- Revenue Growth
- FOA 155.35
- DBVT N/A
- 52 Week Low
- FOA $6.13
- DBVT $2.21
- 52 Week High
- FOA $32.40
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- FOA 54.57
- DBVT 56.17
- Support Level
- FOA $22.75
- DBVT $10.11
- Resistance Level
- FOA $24.17
- DBVT $11.84
- Average True Range (ATR)
- FOA 0.74
- DBVT 0.67
- MACD
- FOA -0.03
- DBVT 0.05
- Stochastic Oscillator
- FOA 61.94
- DBVT 60.06
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.